OBJECTIVE: Despite recommendations that second-generation antipsychotics be used as first-line treatment for schizophrenia, previous studies have shown that blacks are less likely than whites to receive these newer drugs. This study determined the rate at which second-generation antipsychotics were prescribed to whites and blacks with schizophrenia who were treated as outpatients. METHODS: Data were collected from a community mental health clinic affiliated with an academic center in Rochester, New York. Multivariate logistic regression was used to examine the association between race and the receipt of a second-generation antipsychotic. RESULTS: Data were available for 456 patients: 276 whites and 180 blacks. Ninety-five percent received a second-generation antipsychotic. Whites were approximately six times more likely than blacks to receive a second-generation medication, after the analysis controlled for clinical and sociodemographic factors (p<.001). Most of this difference appeared to be driven by a disparity in the use of clozapine. CONCLUSIONS: In this sample, blacks were less likely than whites to receive second-generation antipsychotics, demonstrating a persistent gap in the quality of care for patients with schizophrenia.
OBJECTIVE: Despite recommendations that second-generation antipsychotics be used as first-line treatment for schizophrenia, previous studies have shown that blacks are less likely than whites to receive these newer drugs. This study determined the rate at which second-generation antipsychotics were prescribed to whites and blacks with schizophrenia who were treated as outpatients. METHODS: Data were collected from a community mental health clinic affiliated with an academic center in Rochester, New York. Multivariate logistic regression was used to examine the association between race and the receipt of a second-generation antipsychotic. RESULTS: Data were available for 456 patients: 276 whites and 180 blacks. Ninety-five percent received a second-generation antipsychotic. Whites were approximately six times more likely than blacks to receive a second-generation medication, after the analysis controlled for clinical and sociodemographic factors (p<.001). Most of this difference appeared to be driven by a disparity in the use of clozapine. CONCLUSIONS: In this sample, blacks were less likely than whites to receive second-generation antipsychotics, demonstrating a persistent gap in the quality of care for patients with schizophrenia.
Authors: Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman Journal: Schizophr Res Date: 2008-02-05 Impact factor: 4.939
Authors: Deanna L Kelly; Julie Kreyenbuhl; Lisa Dixon; Raymond C Love; Deborah Medoff; Robert R Conley Journal: Schizophr Bull Date: 2006-12-14 Impact factor: 9.306
Authors: Matthew E Levy; Anne K Monroe; Michael A Horberg; Debra A Benator; Sherry Molock; Rupali K Doshi; Lindsey Powers Happ; Amanda D Castel Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: Kathleen Patchan; Gopal Vyas; Ann L Hackman; Marie Mackowick; Charles M Richardson; Raymond C Love; Ikwunga Wonodi; MacKenzie A Sayer; Matthew Glassman; Stephanie Feldman; Deanna L Kelly Journal: Psychiatr Q Date: 2018-03
Authors: Mark D Williams; Teresa Rummans; Shirlene Sampson; Rebecca Knapp; Martina Mueller; Mustafa M Husain; Max Fink; Keith Rasmussen; Kevin O'Connor; Glenn Smith; George Petrides; Charles H Kellner Journal: J ECT Date: 2008-06 Impact factor: 3.635